BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Covaris, Inc. Introduces Bench-top, AFA-based Process Technology


3/25/2011 7:09:25 AM

WOBURN, Mass., March 25, 2011 /PRNewswire/ -- Covaris Incorporated today announced the introduction of the Bench-top SF220 High Performance Formulation Processing System.

The SF220 system was designed to extend the company's ground-breaking Adaptive Focused Acoustics (AFA) technology to higher volume sample processing. With the ability to process sample volumes from microliters through tens of liters, larger volume application areas such as Pre-clinical formulation, drug delivery systems, and biological processes (such as cell lysis, sonoporation, or transfection) can now "scale-up" the advantages of the proven AFA technology.

The Covaris SF220 system provides a solution for the problem of poorly soluble API's using the proprietary Covaris AFA Technology. For example, adoption of the AFA-based SF220 system for preparation of DMPK formulations has been shown to improve quality of the studies by increasing the bioavailability, while reducing subjective content and improving operational efficiency. Using AFA to accelerate dissolution can improve both the quality and efficiency of the drug development process, with unparalleled reproducibility, precision, and speed. Demonstrated increases of solubility of over 90% have been achieved, while concurrently reducing the process time from over 2 days of stirring to under 3 minutes, and increasing the available API by over 2.5x due to a dramatic reduction in API degradation. According to Jim Laugharn, Founder and CEO, "We at Covaris are very excited about the introduction of the new systems to meet the 'pent-up demand' our current customers have for processing larger sample volumes with AFA technology." At present, Covaris has installed over 1,500 systems in over 30 countries worldwide.

AFA has also been demonstrated to formulate monodisperse, nano-emulsions with mean particle sizes of 20nm and an index below 0.100. Liposomes can be produced using a simple lipid/water combination with the resulting single populations below 100nm. The ability to reduce particle size of a crystalline API in water to below 15nm is possible. All results were achieved using Adaptive Focused Acoustics TM (AFA) with very fast process times, non-contact, and isothermal operating conditions.

The Bench-top scale SF220 system is currently available from Covaris. Pilot scale systems are currently in development.

About Covaris Inc.

Covaris, Inc. is a rapidly growing life science instrument company. Its proprietary instrument platform, based on patented Adaptive Focused Acoustic (AFA) technology brings unsurpassed speed and efficiency to biological and chemical sample preparation. The AFA process, based on shock wave physics, delivers controlled, precise and accurate energy to biological and chemical samples. The process is non-contact, isothermal and rapid. Leading pharmaceutical and biotechnology companies worldwide are using Covaris instruments for DNA shearing, RNA extraction, Compound Dissolution and much more.

Information about Covaris is available at http://www.covarisinc.com

SOURCE Covaris Incorporated



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES